In the second article on pharma’s disclosure of payments in the UK, Andrew McConaghie talks to the PMCPA’s Heather Simmonds about potential complaints, and lessons from the US.
The pharma industry is opening up its business to external scrutiny like never before, spurred on by the need to prove that it is indeed an ethical sector.
The biggest shift is in declaring certain transfers of value made to individual doctors and other health professionals as well as healthcare organisations – which are now being revealed for all to see.
The US was the first country to introduce transparency of payments via the Physician Payments Sunshine Act, a mandatory measure which went live for the first time in September 2014.
The UK and Europe are gearing up to follow suit with the first disclosures due by 1 July 2016.
So what can Europe learn from the US experience? The answer is a lot – and much of it being things to avoid, rather than emulate. This is because the US regulations have proven unpopular with many doctors, and got off to a bad start last year. The American Medical Association, which represents the 200,000 doctors affected by the new law, said the project had been ‘plagued’ by problems of accuracy, and protested that physicians had not been given enough time to review the data published on payments they had received.
To read the article by Andrew McConaghie